Decision: Favourable
Study Title:
A multicentre, randomized, double-blind, placebo-controlled, parallel- group phase 3 study to evaluate the safety and efficacy of masitinib as add-on therapy in patients with mild to moderate Alzheimer’s disease, treated with standard of care: cholinesterase inhibitors, memantine
NREC Code:
23-NREC-CT-019
Decision:
Favourable
Meeting Date:
24/03/2023
Study Type:
CT application
Principal Investigator:
Prof Sean Kennelly
PI Institution:
Tallaght Hospital
Sponsor:
AB Science